List view / Grid view
Eurofins Healthcare Assurance is expanding into China to better serve key industries with local expertise. This move strengthens their commitment to quality assurance and regulatory services on a global scale.
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
Researchers in the US have developed a new CRISPR method for treating genetic conditions using nickases that they say is safer and more effective.
Viral vectors to deliver gene therapies are utilised by clinically approved therapies. However, this method is not the only option for advanced therapeutics. In this piece, Brent Warner, President, Gene Therapy at Poseida Therapeutics, discusses the balance between efficacy and safety in gene therapy, highlighting positive pre-clinical data for non-viral…
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.
